Herbert Cordero Yordan, MD
Cardiovascular Disease · Las Vegas, NVNPI 1619924602
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 971 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among cardiovascular disease clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 971 payments — averaging $39.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$5K
- Medtronic$5K
- W. L. Gore & Associates, Inc.$5K
- Shockwave Medical, Inc$4K
- Abbott$3K
- Boston Scientific$2K
- plus $14K from 54 others
Across 1 payment — averaging $124.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$124
What the payments were for
- Speaking & faculty fees$1,7505%
- Travel & lodging$6812%
- Food & beverage$35,31993%
- Education$2801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$2,065
- CoreValve Evolut$1,801
- COREVALVE EVOLUT R$1,504
- Impella$1,198
- Barostim Neo System$939
- Mitra Clip system$793
- CARDIOMEMS$564
- Sublime 014 Rx PTA Balloon Dilatation Catheter$542
- Sublime Microcatheter, 018, 200cm, Straight$542
- Pounce Thrombectomy System$542
- Pounce Thrombectomy$542
- Pounce Venous Thrombectomy System$542
- TAG Thoracic Endoprosthesis$506
- EXCLUDER AAA Endoprosthesis$390
- Ensite Cardiac Mapping System$342
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$305
- Auryon Laser System 100-120 Vac$268
- GORE TAG Conformable Thoracic Endoprosthesis$266
- GENERAL VASCULAR INTERVENTION$242
- Torus Stent Graft System$231
How this compares
$38,030 in reported general payments places this provider in the 90th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 102 | $146,021 |
| EliquisApixaban | 112 | $144,501 |
| Repatha SureclickEvolocumab | 89 | $100,218 |
| XareltoRivaroxaban | 53 | $79,038 |
| OzempicSemaglutide | 41 | $63,568 |
| JardianceEmpagliflozin | 30 | $45,022 |
| FarxigaDapagliflozin Propanediol | 21 | $34,297 |
| Praluent PenAlirocumab | 15 | $20,524 |
| MounjaroTirzepatide | 12 | $12,331 |
| Ranolazine ErRanolazine | 110 | $7,462 |
| Clonidine | 53 | $6,969 |
| NexletolBempedoic Acid | 14 | $6,506 |
| Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide | 135 | $3,887 |
| Atorvastatin Calcium | 331 | $3,632 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 12 | $3,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $1,454 | $146,021102 claims |
| PfizerEliquis | $61 | $144,501112 claims |
| Johnson & JohnsonXarelto | $890 | $79,03853 claims |
| Novo NordiskOzempic | $299 | $63,56841 claims |
| Boehringer IngelheimJardiance | $28 | $45,02230 claims |
| AstraZenecaFarxiga | $93 | $34,29721 claims |
| Esperion Therapeutics, Inc.Nexletol | $20 | $6,50614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Alfred DanielianLas Vegas$30K
- Dalia HawwassLas Vegas$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.